title: Therapeutic effect of puerarin on non-alcoholic rat fatty liver by improving leptin signal transduction through JAK2/STAT3 pathways.
abstract: In order to investigate the mechanism of the therapeutic effect of puerarin on non-alcoholic fatty liver disease, a non-alcoholic fatty disease male rat model was induced by a high fat diet, all rats were randomly divided into a blank group, model group, simavastatin group and puerarin group. After 4 weeks of drug treatment, the liver was slided to investigate pathological morphology. Elisa was used to measure the total cholesterol (TC), triglyeride (TG) in liver, and leptin content in serum. RT-PCR and Western blotting were employed to detect liver leptin mRNA receptor expression and P-JAK2, P-STAT3 expression levels in the liver respectively. The results showed that puerarin significantly decreased the TG, TC content in liver of the non-alcoholic fatty disease rats, ameliorated steatosis in liver, lowered liver inflammatory reaction, decreased leptin level in serum, and enhanced the expression of leptin receptor mRNA and P-JAK2/P-STAT3 level. All the results demonstrated that puerarin can exhibit therapeutic effect on non-alcoholic fatty liver disease by improving leptin signal transduction through JAK2/STAT3 pathways.
authors.affiliation: Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
authors.forename: Peiyong
authors.initials: P
authors.lastname: Zheng
authors.forename: Guang
authors.initials: G
authors.lastname: Ji
authors.forename: Zansong
authors.initials: Z
authors.lastname: Ma
authors.forename: Tao
authors.initials: T
authors.lastname: Liu
authors.forename: Lianjun
authors.initials: L
authors.lastname: Xin
authors.forename: Hongzhong
authors.initials: H
authors.lastname: Wu
authors.forename: Xin
authors.initials: X
authors.lastname: Liang
authors.forename: Jianwen
authors.initials: J
authors.lastname: Liu
mesh_terms: D000818:Animals; D002784:Cholesterol / Q000097:blood; D004041:Dietary Fats / Q000494:pharmacology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005234:Fatty Liver / Q000188:drug therapy*; D007249:Inflammation / Q000188:drug therapy; D007529:Isoflavones / Q000494:pharmacology / Q000627:therapeutic use*; D053614:Janus Kinase 2 / Q000378:metabolism; D020738:Leptin / Q000097:blood; D050356:Lipid Metabolism / Q000187:drug effects*; D008099:Liver / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use; D029908:Pueraria; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D054411:Receptors, Leptin / Q000378:metabolism*; D050796:STAT3 Transcription Factor / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*; D019821:Simvastatin / Q000494:pharmacology / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
chemical_list: D004041:Dietary Fats; D007529:Isoflavones; D020738:Leptin; D010936:Plant Extracts; D012333:RNA, Messenger; D054411:Receptors, Leptin; D050796:STAT3 Transcription Factor; D014280:Triglycerides; D002784:Cholesterol; D019821:Simvastatin; D053614:Janus Kinase 2; C033607:puerarin